Skip to content

Cost-effectiveness of Controlling CPE

Cost-effectiveness of Strategies to Control the Spread of Carbapenemase-producing Enterobacteriaceae (CPE) in Hospitals

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05272410
Acronym
OPTIM-BHRe
Enrollment
1800
Registered
2022-03-09
Start date
2022-03-31
Completion date
2023-09-30
Last updated
2022-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carbapenemase-producing Enterobacteriaceae Infections

Keywords

CPE spread, CPE infections, CPE deaths

Brief summary

Spread of extensively drug-resistant bacteria (XDR) such as carbapenemase-producing Enterobacterales (CPE) is a major public health problem. Various prevention and control interventions are implemented to limit the transmission of XDR but they are expensive and often disrupt hospital organization. In this study, a mathematical model will be used to study the effectiveness and cost-effectiveness of control strategies to limit the spread of CPE in a general hospital ward. A case-control study will be conducted to estimate the excess length of stay and mortality attributable to CPE colonisation or infection.

Detailed description

Carbapenemase-producing Enterobacterales (CPE) are increasingly common in hospitals and represent a serious health problem. These multidrug-resistant organisms colonise the gastrointestinal tract after direct (person-to-person) or indirect (via contaminated surfaces) transmission and are a common cause of urinary tract infections, ventilator-associated pneumonia and bloodstream infections in healthcare settings. Treatment options for patients infected with CPE are limited leading to high mortality, increased length of hospital stay and hospital costs. The successful implementation of cost-effective infection control measures to prevent CPE spread and infections is key for infection control preventionists and hospital managers. Recommendations to limit the transmission of CPE in healthcare facilities are based on the early detection of asymptomatic carriers, implementation of contact precautions and isolation in single room. In practice, strategies combining various interventions are employed according to the risk assessment and available resources: 1) universal or targeted rectal screening on admission, 2) standard precautions (SP), applied to all patients regardless of their infectious status, 3) contact precautions (CP) for identified carriers or infected patients, 4) isolation in a single room, 5) environmental cleaning, 6) rectal screening of contact patients, i.e. those whose care was provided by the same team as the CPE patient, and/or 7) isolation of carriers in a dedicated area with dedicated nursing staff (DNS), thereafter designated as cohorting. However, these control measures pose challenges such as the high cost of patient's screening and cohorting, requirement for single room isolation or staff shortage for implementing precautions. Moreover, the effectiveness and cost-effectiveness of various CPE control strategies is under-documented. OBJECTIVES: Primary: To evaluate the cost-effectiveness of different strategies combining screening and contact precaution measures to control the spread of CPE in a general medicine ward (GW) using a mathematical model. Secondary: * To assess the impact of CPE colonisation/ infection on patient's outcome (mortality, length of stay) * To analyse the resources used to manage CPE cases * To analyse the care pathway of a CPE case and study whether carrying the CPE represents the opportunity loss for the patient, METHODS AND TOOLS: A dynamic, stochastic model simulates the transmission of CPE by the hands of healthcare workers (HCWs) and the environment in a hypothetical GW. Input parameters are based on data from APHP hospitals and from the literature. 12 strategies are compared to the baseline (no control) and combined different prevention and control interventions: targeted or universal screening at admission (TS or US), contact precautions (CP), isolation in a single room, dedicated nursing staff (DNS) for carriers and weekly screening of contact patients (WS). Time horizon is one year. A hospital perspective is adopted to estimate costs, which included laboratory costs, single room, contact precautions, staff time, i.e. infection control nurse and/or nurses for cohorting, and lost bed-days due to prolonged hospital stay of identified carriers. A case-control study will be conducted to assess the impact of CPE colonization / infection on patient's outcomes. Cases will be the patients newly identified as CPE colonized or infected during the first semester 2016 in the APHP hospital network, i.e. around 450 cases. In the case of hospital CPE outbreak, index and secondary cases will be included. Cases will be followed until discharge from the hospital setting, including rehabilitation or home care. Since all discharges in France, either from public or private HCFs, are registered in the single national hospital discharge database PMSI (HDD), it is possible to link all hospital stays and retrieve the entire hospital course. Controls will be selected in the national HDD on a 1:1 ratio, based on the following matching criteria: absence of known colonization with CPE, age, gender, hospital stay in the same unit as the corresponding case during the 1st semester 2016, same DRG and duration of hospital stays at least as long at the time to colonization in the case. The following information will be collected in cases and controls: * demographic data, country of born (and if so date of entry in France), * Charlson comorbidity score, McCabe score, activity of daily living (ADL) score at discharge from the index hospital stay, * main and secondary DRG in the HDD system, * socioeconomic status, estimated by the address of living (IRIS score), type of registration in the national insurance security, * origin at hospital admission, whether the case is an index or secondary CPE colonized/infected, * whether the case was only colonized or infected, type of Enterobacteriaceae carrying the resistance gene, and type of resistance gene * control measures implemented for controlling the episode: contact precautions, reinforced personnel, dedicated personnel, interruption of admission and transfers * activity of the unit of first admission: number of bed, yearly number of admissions and hospital days A cost-effectiveness analysis will be undertaken to find the most favourable control strategies from the model simulations. Sensitivity analysis will identify the factors that have the greatest impact on the results.

Interventions

None listed

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients infected with emerging highly resistant bacteria at acute care hospital.

Exclusion criteria

* patients infected while hospitalized in intensive care unit.

Design outcomes

Primary

MeasureTime frameDescription
ICER- the ratio of the difference in costs to difference in health benefits12 monthsThe incremental cost-effectiveness ratios (ICER) calculated as the extra annual cost of one strategy relative to another divided by CPE cases avoided by that strategy relative to the other strategy

Secondary

MeasureTime frameDescription
Costs of strategies6 months after the end of the data collectionDescription: costs associated with each strategy (e.g. laboratory costs, cost of single room, contact precautions, staff time)
Number of days when hospital admissions interrupted6 months after the end of the data collectionNumber of days when the presence of EPC in a ward leads to the interruption of new admissions
Number of days when hospital transfers interrupted6 months after the end of the data collectionDescription: Number of days when the presence of EPC in a ward leads to the interruption of transfers
Number of CPE acquisitions6 months after the end of the data collectionNumber of CPE acquisitions observed for each strategy simulated in the model
length of hospital stay of patients6 months after the end of the data collectionlength of hospital stay for cases (CPE infected or colonised patients) and controls
risk of death6 months after the end of the data collectionrisk of in-hospital death for cases (CPE infected or colonised patients) and controls
frequency of employment of dedicated staff6 months after the end of the data collection% of situations where dedicated staff were employed for the management of CPE cases

Contacts

Primary ContactJean Christophe Pr Lucet, Professor
jean-christophe.lucet@aphp.fr+33 140 256 194
Backup ContactIsabelle Pr Durand-Zaleski, Professor
isabelle.durand-zaleski@aphp.fr+33 140 274 143

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026